Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. - Wikidata - awgldk - TriplyDB

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

http://www.wikidata.org/entity/Q34235012

about

The search for novel analgesics: targets and mechanisms Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists Opioid receptors: toward separation of analgesic from undesirable effects Structural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signaling Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene.Opiate pharmacology and relief of pain.Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.Differential expressions of the alternatively spliced variant mRNAs of the µ opioid receptor gene, OPRM1, in brain regions of four inbred mouse strains Review of preclinical studies on treatment of mucositis and associated pain Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Opioids and their receptors: Are we there yet?Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.The N-terminally truncated µ3 and µ3-like opioid receptors are transcribed from a novel promoter upstream of exon 2 in the human OPRM1 gene.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.Synthesis and pharmacology of halogenated δ-opioid-selective [d-Ala(2)]deltorphin II peptide analogues Differential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine Stimulation Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons.Mediation of opioid analgesia by a truncated 6-transmembrane GPCR.Splice variation of the mu-opioid receptor and its effect on the action of opioids.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior Truncated mu opioid GPCR variant involvement in opioid-dependent and opioid-independent pain modulatory systems within the CNS.Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide α-neoendorphin.Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action.Mu opioids and their receptors: evolution of a concept.Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management.Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo.Novel 6β-acylaminomorphinans with analgesic activity.Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107.Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1P.Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.The roles played by highly truncated splice variants of G protein-coupled receptors.μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.Supraspinal inhibitory effects of chimeric peptide MCRT on gastrointestinal motility in mice.Mild, Pd-catalyzed stannylation of radioiodination targets.Breaking barriers to novel analgesic drug development.

P2860

Q24288817-B972E309-88CB-470F-AD49-36D139DC41AE Q26852027-329AAB33-D728-47ED-8D24-7C72FCE4F0BA Q27002925-7CBE68BF-B8C3-4A2C-80B3-E0431BEBCB56 Q27303730-EC0B9BA7-334D-4350-AA72-A16E5FAFF4B6 Q30631761-090103ED-BF3F-4624-992B-57963172BD30 Q33650564-1D66D30D-831B-4664-AFBB-B47A23385993 Q34125112-049D53D3-9D77-45B2-B1B4-D7736C95ACF7 Q34284204-B55048CB-B354-4889-AECD-5A0B61CE70EB Q34400986-19D1A268-BE2A-43D7-99E6-A8E70C090CBB Q34421916-F1981779-F480-4BD9-BA43-00ECB31CB0E2 Q34424009-45ADFFBF-1C0F-4C69-B481-4549B10378F6 Q34437456-BB391CAE-B338-48A6-818B-402756DACAE7 Q34538336-1608483C-4015-4A33-8E75-A569A4B7FF24 Q34926300-3ECDCE2F-EE83-4E12-A848-FEFAD5F833E8 Q34948489-1AC76473-903A-4D17-BE90-9539F74A76C8 Q35007339-BAD9638C-5879-4786-8F96-B45887B7118C Q35684498-EA87A942-9715-4F5A-B370-C08D8EB5A0FA Q35745117-C62B1999-23DD-4914-9BB1-AF8E87B5F045 Q35756505-73069300-B0F5-45B8-857C-23EEC78E1FA0 Q35837099-03EF9D0B-C8FD-404C-929B-F3FA0B75AB8B Q35887385-F8297148-FD26-4A8A-9C3E-9B542B3827F7 Q36040286-7F6B997E-C4F1-4B20-9320-E8FA4B86A330 Q36195269-5FF8A6EE-9973-4245-BF70-8E33A800744E Q36296493-BA0BB500-9A75-4B94-AEA9-6A8E0966668F Q36770675-743F3FA0-B257-49C1-BF33-D33D6F8F08FD Q37049634-E196F490-4115-41FE-9E29-C37028E8D17B Q37175164-B3A0D916-0912-46CF-A2E7-4F75CEB61E21 Q37236111-54972D97-664A-4E27-AE15-F4C356C9D427 Q37258385-1AFFE4B5-D7BD-4B2D-AE15-15A7A522E420 Q37308492-59310BEA-7ECA-4A58-8152-349383008757 Q37340566-4129AE06-B13F-49BB-B0F0-F93E5283A60F Q37553516-6D001356-3486-44E8-B716-7B57EFACAA82 Q37588798-B50329BF-130C-4890-A4A0-2D7D187A2CCA Q37730688-BEE7ECF5-114D-4682-85A4-E4183FE59524 Q37739812-E0F67E45-562A-4F99-B162-59B3E11DFDE2 Q38039520-5CC86630-1EA2-4047-82B9-66AB2E269F9B Q38285112-44504B46-AFF6-4F57-A1D8-C82F8DB27D22 Q39154155-6E3D64ED-3DF4-401F-955A-23138ECC48BC Q39233552-91C74A43-178B-4E54-81D5-0BA836A168C6 Q39360773-73899BCF-DF64-404A-B8F4-EF72897849F3

P2860

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

http://www.wikidata.org/entity/Q34235012

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Truncated G protein-coupled mu ...... algesics lacking side effects.

@ast

Truncated G protein-coupled mu ...... algesics lacking side effects.

@en

Truncated G protein-coupled mu ...... algesics lacking side effects.

@nl

type

label

Truncated G protein-coupled mu ...... algesics lacking side effects.

@ast

Truncated G protein-coupled mu ...... algesics lacking side effects.

@en

Truncated G protein-coupled mu ...... algesics lacking side effects.

@nl

prefLabel

Truncated G protein-coupled mu ...... algesics lacking side effects.

@ast

Truncated G protein-coupled mu ...... algesics lacking side effects.

@en

Truncated G protein-coupled mu ...... algesics lacking side effects.

@nl

P1433

Q34235012-4B3ACD09-F0A9-4CC1-8233-237CC84D0CCD

P1476

Q34235012-827247C2-39AD-44B9-B8EF-5C5291A91CC5

P2093

Q34235012-1971554A-A2D2-49B2-88AC-74A3A81D2FDE

Q34235012-78E1146B-BA32-4C64-BC35-F7A69BA26528

Q34235012-7FF58B37-AC69-416E-AC56-985CD5668C02

Q34235012-806BED2A-23E2-48F9-8B25-B20596403D0E

Q34235012-890FE76A-1B4C-40BF-B32C-859562E47F35

Q34235012-A87D55F7-93CF-46DE-8C41-6C44B1F129E1

Q34235012-B82649CD-5208-4E3A-895B-23A8F175078E

Q34235012-CED98DEC-B612-4421-98F4-9163289296F9

P2860

Q34235012-04842B29-8B5E-424B-A29B-5D0614813BA3

Q34235012-0A7BB5BC-78E2-4A7B-AD4F-221B0B6FD919

Q34235012-0FEC6CFB-6930-4B70-935D-2F04AECDE831

Q34235012-1905B0E9-8F4B-4D4D-9896-7EB32F7A3020

Q34235012-2E0A1404-EB1D-462D-BE5E-1DAF7A5282F3

Q34235012-2F8DA1B7-6896-41D7-AB72-8EEF46819A89

Q34235012-5A768BC5-2DBF-479F-93A3-AD4D4DEE1589

Q34235012-60561974-57E6-4072-8883-E06A82D24E31

Q34235012-6074AD6C-EE1B-4EA5-B714-9BD795F26747

Q34235012-6357ED5D-F19F-4821-A600-32E27ED02B9E

P304

Q34235012-376DE76F-9126-429F-9B08-208406142CE1

P31

Q34235012-AAC8A094-E8CC-4388-AC48-4F93994DA6BA

P356

Q34235012-2CAF3B4B-0890-4904-9BB8-876157ACAE46

P407

Q34235012-96F2B6F8-D830-4F68-9362-9E511BA298E3

P433

Q34235012-61C71BF1-5E4E-412A-B666-CD775859586D

P478

Q34235012-1B80D635-D091-415E-9812-F738D561CE00

P50

Q34235012-40324726-498E-41C4-ABEC-3465BEAA0A50

P577

Q34235012-9F3EC567-BF7A-4A57-BC61-5F454F32F56E

P5875

Q34235012-62C12FB8-594B-491F-8EEE-1C06FE79F333

P698

Q34235012-12F746D5-4ABA-4128-8ABF-6862E61C656C

P921

Q34235012-4218DD52-46E0-4A57-B766-6DC7C87411B5

Q34235012-4939AAB9-B0B6-4798-BCBB-8207DDD86CCB

P932

Q34235012-4E812B43-1095-4877-BDBD-2E577D373EEE

P356

PNAS.1115231108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Truncated G protein-coupled mu ...... algesics lacking side effects.

@en

P2093

Gavril W Pasternak

http://www.w3.org/2001/XMLSchema#string

John Pintar

http://www.w3.org/2001/XMLSchema#string

Lisa Polikar

http://www.w3.org/2001/XMLSchema#string

Maxim Burgman

http://www.w3.org/2001/XMLSchema#string

Michael Ansonoff

http://www.w3.org/2001/XMLSchema#string

Susruta Majumdar

http://www.w3.org/2001/XMLSchema#string

Valerie Le Rouzic

http://www.w3.org/2001/XMLSchema#string

Ying-Xian Pan

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

G-protein-coupled receptor heterodimerization modulates receptor function

Heterodimerization of mu and delta opioid receptors: A role in opiate synergy

Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm

The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog

Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity

Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation

Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia

Molecular insights into mu opioid pharmacology: From the clinic to the bench.

Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.

P304

19778-19783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1115231108

http://www.w3.org/2001/XMLSchema#string

P407

P433

49

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Steven G Grinnell

P577

2011-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51817960

http://www.w3.org/2001/XMLSchema#string

P698

22106286

http://www.w3.org/2001/XMLSchema#string

P921

G protein-coupled receptor

P932

3241767

http://www.w3.org/2001/XMLSchema#string